Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients
Otolaryngology–Head and Neck Surgery · 2026
DOI: 10.1002/ohn.70231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2026. Verfasst von Rachel B Kutler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian/Columbia Uni…. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Objective
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are approved to treat obstructive sleep apnea (OSA), yet their use in an OSA population has not been characterized. This study evaluates GLP‐1 RA use in patients presenting to a sleep surgery clinic. Study Design Retrospective.
Setting
Tertiary care institution.
Methods
Patients with OSA who presented to our sleep surgery clinic between October 2023 and March 2025 with available sleep studies were included (n = 384). Demographic data, body mass index (BMI), apnea‐hypopnea index (AHI), OSA history, GLP‐1 RA prescription data, and usage details were collected through chart review. Eligibility for GLP‐1 RA was defined by FDA drug labeling criteria, with diabetes, obesity, or BMI ≥ 27 kg/m² with a weight‐related comorbidity.
Results
The cohort had mean age 53.3 ± 14.8 years, BMI 29.4 ± 5.7 kg/m 2 , and AHI 28.7 ± 24.2 events/h. Most patients (52.1%) had tried CPAP. Among the full cohort (n = 384), 249 patients (64.8%) met FDA‐approved drug labeling criteria for GLP‐1 RA use, and there were 70 (28.1%) current GLP‐1 RA users among eligible patients. Semaglutide (54.8%) and tirzepatide (27.4%) were the most prescribed. The most common reasons for discontinuing or changing GLP‐1 RA types were insurance‐related issues and adverse effects. Among eligible patients, having Medicaid was associated with lower likelihood of using GLP‐1 RAs (adjusted odds ratio 0.25, P = .04) while BMI ≥30 kg/m 2 (adjusted odds ratio 3.45, P < .001) was associated with higher likelihood.
Conclusion
Among sleep surgery clinic patients, a large proportion were eligible for GLP‐1 RA use, and utilization was high compared to that of the general population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York, USA.
- Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, New York, USA.
- Center of Excellence for Sleep & Circadian Research, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
- Division of General Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Kutler, R. B., Lin, A., Zhang, L., Trackey, P., Rivera-Diaz, A., Jelic, S., St-Onge, M. P., & Cai, Y. (2026). Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70231
Vancouver
Kutler RB, Lin A, Zhang L, Trackey P, Rivera-Diaz A, Jelic S, et al. Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70231
BibTeX
@article{Kutler2026,
author = {Kutler, Rachel B and Lin, Allison and Zhang, Lauren and Trackey, Paul and Rivera-Diaz, Andrea and Jelic, Sanja and St-Onge, Marie-Pierre and Cai, Yi},
title = {Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2026},
doi = {10.1002/ohn.70231}
}
EUVIMED